Cardiovascular Systems’ (CSII) Hold Rating Reiterated at Raymond James Financial
Cardiovascular Systems (NASDAQ:CSII)‘s stock had its “hold” rating reiterated by research analysts at Raymond James Financial in a report issued on Monday.
Several other equities research analysts have also issued reports on CSII. BidaskClub lowered shares of Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price (down previously from $37.00) on shares of Cardiovascular Systems in a report on Thursday, October 26th. Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Citigroup began coverage on shares of Cardiovascular Systems in a report on Thursday, September 21st. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Cardiovascular Systems currently has a consensus rating of “Hold” and an average target price of $38.00.
Shares of Cardiovascular Systems (CSII) traded down $0.60 during trading hours on Monday, hitting $24.15. 113,500 shares of the company’s stock were exchanged, compared to its average volume of 271,055. Cardiovascular Systems has a 1-year low of $23.00 and a 1-year high of $33.11. The stock has a market cap of $791.23, a PE ratio of 1,237.50 and a beta of 2.52. The company has a quick ratio of 3.83, a current ratio of 4.30 and a debt-to-equity ratio of 0.18.
A number of institutional investors and hedge funds have recently made changes to their positions in CSII. BNP Paribas Arbitrage SA raised its holdings in shares of Cardiovascular Systems by 160.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock valued at $166,000 after purchasing an additional 3,165 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new position in shares of Cardiovascular Systems in the 2nd quarter worth approximately $204,000. Legal & General Group Plc grew its position in shares of Cardiovascular Systems by 2.9% in the 2nd quarter. Legal & General Group Plc now owns 7,763 shares of the medical device company’s stock worth $249,000 after buying an additional 216 shares during the last quarter. Advisor Group Inc. grew its position in shares of Cardiovascular Systems by 0.4% in the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock worth $263,000 after buying an additional 35 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Cardiovascular Systems by 34.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock worth $265,000 after buying an additional 2,115 shares during the last quarter. Institutional investors own 75.05% of the company’s stock.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.